SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Search
Partnership with Precision Health Research, Singapore
Boehringer Ingelheim joins forces with Precision Health Research, Singapore with the aim of transforming healthcare and improving patient outcomes in Singapore and beyond.
Research & Development
Research & Development
Immuno-Oncology
We are developing complementary platforms (including, T Cell Engagers, oncolytic viruses, and cancer vaccines), which have the potential to turn cold tumors hot, extending the benefits of immunotherapy to more people.
BI Focuses COVID-19 Clinical Research on Alteplase
BI focuses its COVID-19 therapy research on the development of alteplase as a potential treatment for COVID-19 patients with severe breathing problems
A passion for research which addresses unmet medical needs
Eric Haaksma, Head of Global Innovation Animal Health, explains why his professional purpose is rooted in helping drive advancements in scientific research
Human Pharma Research & Development Approach
Human Pharma Research & Development Approach
Targeting Tumor Stroma
Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients
Boehringer Ingelheim collaborates with Circle Pharma
Boehringer Ingelheim collaborates with Circle Pharma to develop a first-in-class cyclin RxL inhibitor that can halt the growth of cancer cells
Data Science
Revolutionizing research and development with data driven insights
Oncology
Human Pharma Clinical Pipeline Oncology therapeutic area
Inauguration of new integrated Asian Veterinary R&D Center in China
Boehringer Ingelheim confirms its commitment to growth in China with the investment of 19 million euros in its new integrated Asian Veterinary Research & Development Center
2018 Animal Welfare Medals
2018 Animal Welfare Medals: Boehringer Ingelheim recognizes outstanding research in cattle, equine, swine, as well as small animals and pet categories
Collaboration in Oncology
Oncology is a fast-moving, challenging and complex field and only with collaboration between different disciplines, we can be able to win the fight against cancer.
Boehringer Ingelheim advances SIRP immune-oncology program
Boehringer and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
Four Pillars Cancer Immunology
Boehringer Ingelheim is focusing cancer immunology research on T cell engagers, cancer vaccines, oncolytic viruses and immune & stromal modulation
Boehringer Ingelheim acquires Nerio Therapeutics
Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline by adding an innovative preclinical program with the acquisition of Nerio Therapeutics
Retinal Health Research
Our research is targeting key mechanisms in the pathogenesis of retinal diseases – vascular dysfunction, neuronal dysfunction and neuronal inflammation.
Central Nervous System Diseases
Find out more about our research and development in central nervous system diseases
collaboration-Yale
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
Cardio-Renal-Metabolic Research
Read about our patient-centric approach to cardio-renal-metabolic disease research.
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
DCRI-collaboration-empact-mi
Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction
Research-collaboration-Gubra-obesity-treatment
Boehringer Ingelheim and Gubra enter collaboration to identify and validate targets and innovative peptides for the treatment of obesity.
“My ultimate goal is to cure cancer”
Norbert Kraut, our Global Head of Cancer Research, shares how we are advancing science to bring new treatment options for people living with cancer.